Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 18:17 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial Magnetic Resonance Imaging Sub-study
NCT03783754 · The George Institute · NA · terminated · last registry update 2021-05-25 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Not feasible to continue” | – | Registry record, The George Institute |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against AGTR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-05-09Results posted on the registry: University of Alabama at Birmingham, Losartan + Losartan (NCT02373241)
- 2022-05-04Results posted on the registry: University of Minnesota, Losartan (NCT04311177)
- 2022-04-27Also stopped (withdrawn): The University of Texas Health Science Center, Houston, Candesartan + Placebo (NCT04430959)
- 2022-04-11Phase 3 first posted: Cristina Avendaño Solá, Candesartan (NCT05321875)
- 2022-03-24Also stopped (terminated): Bassett Healthcare, Losartan + Placebo (NCT04328012)
- 2022-03-03Also stopped (withdrawn): Stanford University, Angiotensin-(1-7) + Placebo (NCT04570501)
- 2022-02-14Phase 3 first posted: I.M. Sechenov First Moscow State Medical University, mycophenolate mofetil 2 g per day + azathioprine of 150 [75; 150] mg per day (NCT05237323)
- 2022-01-20Phase 3 first posted: Hanmi Pharmaceutical Company Limited, HCP1904-3 + RLD2001-1 (NCT05199129)
- 2022-01-20Phase 3 first posted: Universität Münster, Angiotensin II + Control (NCT05199493)
- 2022-01-19Results posted on the registry: University of Delaware, Hypertensives (NCT03371823)
- 2022-01-19Also stopped (terminated): University of Delaware, Hypertensives (NCT03371823)
- 2022-01-10Phase 3 first posted: Dimerix Bioscience Pty Ltd, DMX-200 + Placebo (NCT05183646)
- 2021-12-01Results posted on the registry: Norwegian University of Science and Technology, Betablockers or other preventive drugs based on primary headache type (NCT00159588)
- 2021-11-18Results posted on the registry: Mayo Clinic, Candesartan + Placebo (NCT01678794)
- 2021-11-15Also stopped (terminated): University Hospital, Limoges, Candesartan (NCT03688633)
- 2021-11-08Phase 3 first posted: Brainfarma Industria Química e Farmacêutica S/A, fixed-dose of olmesartan 20mg/40 mg + indapamide 1,5 mg + Isolated drugs Olmesartan (20 mg or 40 mg) and Indapamide (1,5 mg) (NCT05110898)
- 2021-10-21Results posted on the registry: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Losartan potassium + Placebo losartan capsule (NCT03467217)
- 2021-10-21Also stopped (terminated): National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Losartan potassium + Placebo losartan capsule (NCT03467217)
- 2021-10-08Also stopped (terminated): Novartis Pharmaceuticals, EMA401 + Placebo (NCT03297294)
- 2021-10-08Also stopped (terminated): Novartis Pharmaceuticals, EMA401 + Placebo (NCT03094195)
- 2021-09-23Also stopped (suspended): Sun Yat-sen University, a drug against AGTR1 (NCT02471599)
- 2021-09-01Results posted on the registry: National Research Center for Preventive Medicine, Moxonidine + Bisoprolol (NCT02355821)
- 2021-07-28Results posted on the registry: Menarini Group, OM 40 + OM/HCTZ 40/12.5 (NCT00441350)
- 2021-07-27Results posted on the registry: Travere Therapeutics, Inc., RE-021 (Sparsentan) + Irbesartan (NCT01613118)
- 2021-06-15Phase 3 first posted: Laboratorios Silanes S.A. de C.V., Losartan/Chlorthalidone in fixed dose + Losartan + hydrochlorothiazide in fixed dose (NCT04927299)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision